Extended regimens of high-dose VEGF antagonists for the treatment of angiogenic eye disorders.

CL202503988A1Pending Publication Date: 2026-07-03REGENERON PHARMACEUTICALS INC +1

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: CL202503988
Authority / Receiving Office: CL · CL
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-06-21
Filing Date: 2025-12-17
Publication Date: 2026-07-03

Application Information

Patent Timeline

21 Jun 2024

Priority

17 Dec 2025

Application

CL202503988

03 Jul 2026

Publication

CL202503988A1

IPC: A61K38/17; A61K47/02; A61K47/22; A61K47/26; A61P27/02; C07K14/71

CPC: A61K38/179; C07K14/71; A61P27/02; A61K47/183; A61K9/0048; A61K47/02; A61K47/22; A61K47/26

Inventors: Robert L. VITTI; Alyson J. BERLINER

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The present invention relates to regimens for the treatment of angiogenic eye disorders such as nAMD, DR and DME, characterized by high doses of aflibercept and extended periods between doses.

Need to check novelty before this filing date? Find Prior Art